458 research outputs found
Inhibitory effect on ovarian cancer ALDH+ stem-like cells by Disulfiram and Copper treatment through ALDH and ROS modulation
BACKGROUND:
Disulfiram (DSF) is a drug used for treatment of alcoholism that has also displayed promising anti-cancer activity. It unfolds its effects by inhibiting the enzyme activity of aldehyde dehydrogenase (ALDH) isoforms.
METHODS:
MTT assay, spheroid formation, clonogenicity assay, qRT-PCR, and ALDH enzyme activity analysis were performed using ovarian cancer cell lines IGROV1, SKOV3 and SKOV3IP1. Cell cycle analyses and measurement of intracellular reactive oxygen species (ROS) were carried out by flow cytometry. ALDH+ and ALDH- cells were isolated by FACS sorting.
RESULTS:
ALDH activity was inhibited in ovarian cancer stem cells (the proportion of ALDH+ cells was reduced from 21.7% to 0.391%, 8.4% to 0%, 6.88% to 0.05% in cell lines IGROV1, SKOV3, and SKOV3IP1, respectively). DSF with or without the cofactor copper (Cu2+) exhibited cytotoxicity dose- and time-dependent and enhanced cisplatin-induced apoptosis. DSF + Cu2+ increased intracellular ROS levels triggering apoptosis of ovarian cancer stem cells (CSC). Significantly more colony and spheroid formation was observed in ALDH+ compared with ALDH- cells (P < 0.01). Moreover, ALDH+ cells were more resistant to cisplatin treatment compared with ALDH-cells (P < 0.05) and also exhibited a lower basal level of ROS. However, no significant difference in ROS accumulation nor in cellular viability was observed in ALDH + cells in comparison to ALDH- cells after pre-treatment with DSF (0.08 μM).
CONCLUSION:
Our findings provide evidence that DSF might be employed as a novel adjuvant chemotherapeutic agent in combination with cisplatin for treatment of ovarian cancer
A Meta-Analysis
Background p16INK4a is a tumor suppressor protein which is induced in cells
upon the interaction of high-risk HPV E7 with the retinoblastoma protein by a
positive feedback loop, but cannot exert its suppressing effect. Previous
reports suggested that p16INK4a immunostaining allows precise identification
of even small CIN or cervical cancer lesions in biopsies. The prognostic value
of overexpressed p16INK4a in cervical cancer has been evaluated for several
years while the results remain controversial. We performed a systematic review
and meta-analysis of studies assessing the clinical and prognostic
significance of overexpression of p16INK4a in cervical cancer. Methods
Identification and review of publications assessing clinical or prognostic
significance of p16INK4a overexpression in cervical cancer until March 1,
2014. A meta-analysis was performed to clarify the association between
p16INK4a overexpression and clinical outcomes. Results A total of 15
publications met the criteria and comprised 1633 cases. Analysis of these data
showed that p16INK4a overexpression was not significantly associated with
tumor TNM staging (I+II vs. III+IV) (OR = 0.75, 95% confidence interval [CI]:
0.35–1.63, P = 0.47), the tumor grade (G1+ G2 vs. G3) (OR = 0.78, 95% CI:
0.39–1.57, P = 0.49), the tumor size (<4 vs. ≥4 cm) (OR = 1.10, 95% CI:
0.45–2.69, P = 0.83), or vascular invasion (OR = 1.20, 95% CI: 0.69–2.08, P =
0.52). However, in the identified studies, overexpression of p16INK4a was
highly correlated with no lymph node metastasis (OR = 0.51, 95% CI: 0.28–0.95,
P = 0.04), increased overall survival (relative risk [RR]: 0.42, 95% CI:
0.24–0.72, P = 0.002) and increased disease free survival (RR: 0.60, 95% CI:
0.44–0.82, P = 0.001)
CIN2+ detection of the HPV DNA Array genotyping assay in comparison with the Cobas 4800 HPV test and cytology
BACKGROUND:
HPV DNA Array is an E1-targeting PCR genotyping test, with capability of distinguishing 18 high-risk (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) and 11 low-risk HPV types (6, 11, 40, 42, 44, 54, 67, 69, 70, 85, 97). HPV DNA Array uses multiplex PCR for E1-gene sequence amplification. The amplicons are detected and genotyped by reverse hybridization to immobilized DNA probes spotted as triplets in single 96 well-plate wells and read by AID ELISPOT reader.
METHODS:
Aim of the study was to evaluate the clinical performance of the assay against internationally accepted and FDA approved Cobas 4800 HPV test (Roche Diagnostics). Study population comprised of 500 cervical samples.
RESULTS:
HPV DNA Array demonstrated a very high sensitivity of 100% for CIN2+ and 100% for CIN3+ detection, same as Cobas 4800. HPV DNA Array showed greater sensitivity for CIN2+ detection than cytology (100% vs. 13.6%). The agreement to Cobas 4800 for HPV detection, irrespective of type, was 81.4% with κ = 0.613. The agreement for HPV 16 was 92.8% (κ = 0.929), and for HPV 18 54.2% (κ = 0.681).
CONCLUSION:
HPV DNA Array demonstrated good clinical performance for detection of high-grade lesions, and may be considered for usage in a screening setting
Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines
The chemotherapeutic agent cisplatin typically induces apoptosis by inhibiting the cell cycle. Cancer Stem Cells (CSCs), which are a proliferative quiescent and slowly-cycling cell population, are less sensitive and therefore frequently spared from toxic effects. Thus, it remains a priority to increase the sensitivity of CSCs to cisplatin-based chemotherapy, or to specifically target CSCs to improve the therapeutic outcome in breast cancer. Disulfiram (DSF) is a drug used clinically for alcoholism treatment that has displayed promising anti-cancer activity in vitro and in cancer xenografts in breast cancer. Our study provides evidence that DSF inhibits Aldehyde dehydrogenase (ALDH) enzyme activity, inhibits the expression of stemness-related transcription factors (Sox, Nanog, Oct) in CSC derived from breast cancer cell lines, and modulates intracellular reactive oxygen species (ROS) generation. Importantly, our research proved that ALDH + stem-like cells play important roles in the resistance to the conventional chemotherapeutic agent cisplatin. DSF enhances the cytotoxic effect of cisplatin through inhibiting the stemness and by overcoming cisplatin resistance of ALDH + stem-like cells. A quantitative measurement showed the synergistic effect of DSF and cisplatin. Further, we show that ALDH+ cancer stem-like cells and ALDH- bulk cancer cells have different intrinsic ROS levels, what may explain differences in susceptibility to cisplatin treatment. Importantly, this difference is eliminated by DSF treatment making both cell types similarly susceptible for cytotoxic effects by cisplatin. These findings may influence chemotherapeutic treatment approaches in the future
a meta-analysis of the 5-year efficacy and safety
Background The objective of this study was to compare the efficacy and safety
of taxane (docetaxel or paclitaxel), cisplatin, and fluorouracil (Tax-PF) with
cisplatin plus fluorouracil (PF) regimen by a meta-analysis of data retrieved
from the literature. Methods Seven randomized clinical trials were identified,
which included patients with advanced head and neck cancer who underwent
induction chemotherapy with either a Tax-PF or PF protocol. The outcomes
included the 3-year and 5-year overall survival (OS) and progression-free
survival (PFS), overall response rate (ORR) and different types of adverse
events. Results The 3-year OS rate (HR: 1.14; 95% CI: 1.03 to 1.25; P =
0.008), 3-year PFS rate (HR: 1.24; 95% CI: 1.08 to 1.43; P = 0.002), 5-year OS
rate (HR: 1.30; 95% CI, 1.09 to 1.55;P = 0.003), 5-year PFS rate (HR: 1.39;
95% CI, 1.14 to 1.70; P = 0.001) and ORR to chemotherapy (OR 1.66; 95% CI,
1.35 to 2.05; P < 0.001) of the patients in the Tax-PF group were
statistically superior to those in the PF group. In terms of toxicities, the
incidence of febrile neutropenia (OR 2.36; 95% CI, 1.62 to 3.46; P < 0.001),
alopecia (OR 8.22; 95% CI, 3.99 to 16.92; P < 0.001), diarrhea (OR 1.57; 95%
CI, 1.05 to 2.36; P = 0.03) and leukopenia (OR 2.79; 95% CI, 1.86 to 4.21; P <
0.001) was higher in the Tax-PF group. Conclusion The Tax-PF induction
chemotherapy improved PFS and OS, and the ORR was better as compared to PF-
based therapy regimens at the cost of a higher incidence of adverse events
implications for HPV vaccination policies
Background In Germany, immunization against human papillomaviruses (HPV) is
free of charge for all females aged 12 to 17 years. Since HPV infection rates
rise soon after first intercourse, immunization against HPV should be
completed before sexual debut. Knowledge of country-specific data on age at
first intercourse and related risk factors is important to optimize prevention
of HPV and other sexually transmitted infections. Therefore, the primary aim
of this study was to describe sexual behavior in young women in Germany.
Secondary aims were to identify factors that are (i) associated with younger
age at first intercourse and (ii) with HPV vaccine uptake. Methods Between
2010 and 2012, we conducted a cross-sectional study among randomly selected
women aged 20 to 25 years in Germany. We used a structured, self-administered
questionnaire to collect sociodemographic data, information on sexual habits
such as age at first intercourse, and information on HPV vaccine uptake. We
used univariate and multivariate logistic regression analyses to identify
factors associated with younger age at first intercourse and with HPV vaccine
uptake. Results A total of 823 women (response rate: 14.2%) participated, 785
(95.4%) of which reported having had intercourse already. 70% of these women
experienced first intercourse before the age of 18 years. However, less than
5% were younger than 14 years at sexual debut. Younger age at first
intercourse was independently associated with a higher number of sexual
partners, smoking, and past pregnancies. HPV vaccine uptake was associated
with higher education, whereas smoking and a migrant background reduced the
chance of being vaccinated. Conclusion In Germany, only a small proportion of
women experienced first intercourse before the age of 14 years. Younger age at
first intercourse was associated with behavior that might increase the risk of
HPV infections or other sexually transmitted infections. Therefore, to
optimize the HPV vaccination strategy, HPV vaccination series should be
completed before the age of 14 years in Germany
Blockade of ALDH in Cisplatin-Resistant Ovarian Cancer Stem Cells In Vitro Synergistically Enhances Chemotherapy-Induced Cell Death
Epithelial ovarian cancer (EOC) is the leading cause of gynecological cancer-related death. The high mortality and morbidity associated with EOC are mostly due to late diagnosis and chemotherapy drug resistance. Currently, the standard first-line chemotherapy regimen is systemic administration of platinum-based chemotherapy combined with a taxane. A major problem besides cisplatin resistance (occurring in nearly one-third of patients) is the greater toxicity of the drug combinations. A synergistic treatment with drug supporting activity could maximize the cytotoxic effects of chemotherapeutic agents on tumor cells while decreasing the dosage of each drug to potentially reduce toxicity. The ALDH-blocking agent Disulfiram (DSF), a clinically approved drug used for alcoholism treatment, has displayed promising anti-cancer activity. We previously described that blocking ALDH activity enhances the induction of apoptosis, especially in ovarian cancer stem cells treated with chemotherapeutic agents. In this study, we further investigated the synergistic effect of DSF in combination with cytotoxic chemotherapeutic drugs. The concentration of each chemotherapeutic agent could be significantly reduced with sustained efficacy on tumor cell apoptosis in cell lines in vitro (Dose-Reduction Index at IC50 from 1 to 50). Moreover, the potential chemo-sensitizing effects of DSF on ALDH-associated cisplatin-resistant ovarian cancer stem cells were also investigated and shown that in contrast to its high resistance to cisplatin, the cisplatin-resistant cells remain very sensitive to DSF-induced cytotoxicity (apoptosis and necrosis: cisplatin-resistant cells vs. parental cells: 60.4% vs. 20.5%). In combination with DSF and cisplatin, relatively more apoptosis and necrosis were induced in cisplatin-resistant cells than in their parental cells (apoptosis and necrosis: cisplatin-resistant cells vs. parental cells: 81.5% vs. 50.1%). A transcriptome analysis identified that ALDH was mainly enriched in the cancer-associated fibroblasts and showed that ALDH plays roles in responding to oxidative stress, metabolisms, and energy transition in the ALDH-associated cisplatin-resistant ovarian cancer stem cells. In conclusion, our data demonstrate a key role of ALDH-associated cisplatin-resistant cancer stem cells and identifies DSF as a potential adjuvant for a rational protocol design by computational quantitative assessment in vitro on ovarian cancer cell lines. Our work contributes to resolving the ALDH-associated cisplatin resistance and provides a resource for the development of novel chemotherapeutic regimens
A meta-analysis
There is a lack of predictive biomarkers that can identify patients with head
and neck squamous cell carcinoma (HNSCC) who will experience treatment failure
and develop drug resistance, recurrence, and metastases. Cancer stem-like
cells (CSC) were identified as a subset of cells within the tumor in a variety
of solid tumors including HNSCC. CSC are considered the tumor-initiating
population responsible for recurrence or metastasis and are associated with
therapy resistance. This meta-analysis including fourteen studies with
altogether 1258 patients updates and summarizes all relevant data on the
impact of ALDH1+ CSC on the prognosis of HNSCC and its association with
clinicopathological parameters. ALDH1 expression is highly correlated with
tumor differentiation (G3 vs. G1+G2; odds ratio = 2.85. 95% CI: 1.72–4.73,
P<0.0001) and decreased overall survival (relative risk = 1.77. 95% CI:
1.41–2.22, P<0.0001) if one out of seven studies was excluded because of
heterogeneity. These findings provide insights into the understanding of more
aggressive tumor phenotypes and also suggest that the prognostic value
provided by HNSCC-subtyping by CSC frequency warrant further clinical
investigation
Анализ темпа падения дебитов нефти и жидкости при использовании технологии многостадийного гидроразрыва пласта юрских отложений на горизонтальном участке ствола скважины на месторождениях Западной Сибири
Semantic Integration of Cervical Cancer Data Repositories to Facilitate Multicenter Association Studies: The ASSIST Approach
The current work addresses the unifi cation of Electronic Health Records related to cervical cancer into a single medical knowledge source, in the context of the EU-funded ASSIST research project. The project aims to facilitate the research for cervical precancer and cancer through a system that virtually unifi es multiple patient record repositories, physically located in different medical centers/hospitals, thus, increasing fl exibility by allowing the formation of study groups “on demand” and by recycling patient records in new studies. To this end, ASSIST uses semantic technologies to translate all medical entities (such as patient examination results, history, habits, genetic profi le) and represent them in a common form, encoded in the ASSIST Cervical Cancer Ontology. The current paper presents the knowledge elicitation approach followed, towards the defi nition and representation of the disease’s medical concepts and rules that constitute the basis for the ASSIST Cervical Cancer Ontology. The proposed approach constitutes a paradigm for semantic integration of heterogeneous clinical data that may be applicable to other biomedical application domains
- …